Sellas Life Sciences Group, Inc. (SLS) Stock Price & Analysis
Sellas Life Sciences Group, Inc. (SLS) fell 3.76% to USD 7.68 as of June 9, 2026 at 23:53 UTC, according to Nexqual real-time market data.
SLS last closed at USD 7.98; the session ranged USD 7.46–8.09 on volume of 6,839,312 shares. Market capitalization is $1.51B, with a 52-week range of USD 1.39–9.51 (NCM). Source: Nexqual, June 9, 2026 at 23:53 UTC.
Key Statistics (as of June 9, 2026 at 23:53 UTC)
| Price | USD 7.68 |
|---|---|
| Change | ▼ 3.76% (down) |
| Previous Close | USD 7.98 |
| Open | USD 8 |
| Day Range | USD 7.46 – 8.09 |
| 52-Week Range | USD 1.39 – 9.51 |
| Volume | 6,839,312 shares |
| Market Cap | $1.51B |
| Exchange | NCM |
Technical Analysis (SLS)
Nexqual's technical model rates SLS "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:53 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.52 (neutral) |
| vs SMA50 | Above (USD 6.05) |
| MACD | 0.67 (positive) |
Analyst Ratings (SLS)
Wall Street analysts rate SLS "None" based on 2 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of June 9, 2026 at 23:53 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (SLS)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.05 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.05 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.06 vs est -0.08 ▲ beat |
| 2025-06-30 | USD -0.07 vs est -0.08 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financials & Fundamentals (SLS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -43.59% |
| Debt / Equity | 0.81 |
| Current Ratio | 17.22 |
| Total Cash | $107.10M |
| Total Debt | $871,000 |
| Free Cash Flow | $-17.66M |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Financial Health Score (SLS)
Nexqual rates Sellas Life Sciences Group, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:53 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $107M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$28M |
| Efficiency | Critical — ROE -44%, ROA -25.4% |
Ownership (SLS)
| Insider Ownership | +0.41% |
|---|---|
| Institutional Ownership | +27.62% |
| Shares Outstanding | 196.63M |
| Float | 185.23M |
| Short % of Float | +30.81% |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
Leadership (SLS)
Sellas Life Sciences Group, Inc. is led by Angelos M. Stergiou M.D., ScD h.c. (age 49), Founder, President, CEO & Director, per Nexqual as of June 9, 2026 at 23:53 UTC.
| Founder, President, CEO & Director | Angelos M. Stergiou M.D., ScD h.c. (age 49) |
|---|---|
| Senior VP & CFO | John Thomas Burns (age 40) |
Major Backers & Investors (SLS)
Notable institutional backers of Sellas Life Sciences Group, Inc. include Fidelity, Marshall Wace LLP, Jones Financial Companies, L.L.L.P., according to Nexqual as of June 9, 2026 at 23:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.09% |
| Marshall Wace LLP | 1.04% |
| Jones Financial Companies, L.L.L.P. | 0.85% |
| Morgan Stanley | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.22% |
| BlackRock | 9.17% |
| State Street | 6.94% |
| Geode Capital | 1.99% |
| Northern Trust | 0.65% |
Source: Nexqual, June 9, 2026 at 23:53 UTC.
From Sellas Life Sciences Group, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLSI | Greenwich LifeSciences, Inc. | USD 22.23 | ▼ 0.09% |
| IMMP | Immutep Limited | USD 0.37 | ▼ 2.92% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| XBIO | Xenetic Biosciences, Inc. | USD 3.08 | ▼ 0.23% |
| VERU | Veru Inc. | USD 3.1 | ▼ 8.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:53 UTC. This page is informational and not investment advice.